AAV2.5T Serotype
Chimeric serotype combining AAV2 and AAV5 capsid sequences for enhanced muscle transduction with improved tissue distribution.
| Tropism | Skeletal muscle, cardiac muscle |
|---|
Characteristics
Hybrid capsid structure combining AAV2 and AAV5 sequences. Enhanced muscle transduction efficiency versus parental serotypes. Improved intramuscular spread. Reduced immunogenicity profile.
Applications
Duchenne muscular dystrophy gene therapy. Limb-girdle muscular dystrophies. Cardiac gene therapy applications.
Sequence1 bp
Sign in to view the full sequence.
Sign inReferences
- 1.Bowles et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther — Bowles 2012 AAV2.5T
